

## **International Journal of Advance and Applied Research**

www.ijaar.co.in

ISSN - 2347-7075 Peer Reviewed Vol.9 No.6 Impact Factor - 7.328
Bi-Monthly
July - Aug 2022



# TRIAZOLE DERIVATIVES AND THEIR BIOLOGICAL POTENTIAL: A REVIEW

### Rupali Somnath Endait

Assistant Professor, Department of Chemistry, Radhabai Kale Mahila Mahavidyalaya, Ahmednagar-414001, Maharashtra, India

Corresponding Author- Rupali Somnath Endait

Email id: <a href="mailto:rupaliendait@gmail.com">rupaliendait@gmail.com</a>
DOI- 10.5281/zenodo.7069830

#### Abstract

Azoles are nitrogen containing cyclic compounds with great importance in the field of pharmacology. Almost all azoles and their compounds shows various vital biological properties like antimalarial, anti-tubercular, anti-inflammatory, antibacterial, antileishmanial, antifungal, etc. so synthesis of azoles is now adays interested area for the researchers. Triazole is five membered, nitrogen containing aromatic cyclic system. To synthesize azoles different methods are used and they possess different therapeutics properties. This review contains structural development in triazole with their various biological activities.

#### Introduction

In the recent era number of heteroaromatic compounds are known and are used to treat fungal infections, among them azole molecule shows better antifungal property. Albaconazole, Fluconazole, Voriconazole, etc are commonly used antifungal moieties. Fluconazole is first synthetic antifungal agent which contains triazole and it is used in the treatment of systemic candida infections, fungal infections as Cryptococcal meningitis,

oropharyngeal and esophageal candidiasis. acts It is also cvtochrome P450 (CYPs) enzyme inhibitor<sup>1</sup> in human, Vitamin d3 25protein. hvdroxvlase activity with Voriconazole is also good antifungal agent and used to cure fungal infections. invasive candidiasis It also showscaused by any kind of candida, Scedosporium, Penicilliosis and Fusarium. Due to its easy metabolism by hepatic cytochrome P450, it interacts with many kinds of drugs

F Albaconazole

Fluconazole

Voriconazole

Figure 1: Common triazole containing antifungal agents

Along with antifungal activities triazole have broad spectrum of other biological activities like anti-tubercular<sup>2</sup>, antitumor<sup>3</sup>, anti-inflammatory<sup>4</sup>,

antimycobacterial<sup>5</sup>, antiviral<sup>6</sup>, antimalarial<sup>7</sup>, antileishmanial<sup>7</sup>, antioxidant<sup>8</sup>, etc. Triazole motif attracts the most of the researchers due to their

importance in pharmacological field. Most of the chemist works on synthesis and biological evaluation of substituted heteroaromatic triazoles as antifungal agent. Isloor and co-workers<sup>9</sup> have synthesised new derivatives of triazole 4-[(3-substituted-1*H*-pyrazol-4-

yl)methyleneamino]-5-substituted-2-[(4-

methylpiperzine-1-yl)methyl]-2H-1,2,4-triazole-3(4H)-thiones (1) and evaluated for their antibacterial and antifungal activity. Some of the compounds from the series were found to show significant antifungal activity.

Demirayak and co-workers<sup>10</sup> reported the synthesis of 3-arylamino-5-[2-(substituted imidazole-1-yl or benzimidazol-1-yl) ethyl]-1,2,4-triazole compounds (2), furthermore they were screened for antifungal activity against the strains Candida glabrata and Candida albicans. Some of the compounds may consider as potential antifungal agents.

$$\begin{array}{c|c} & H \\ N & N \\ N & N \\ N & N \\ \end{array}$$

Sangshetti and co-workers<sup>11</sup> have synthesised 1,2,4 oxadiazole containing 1,2,3 triazole derivatives (3) and screened them for antifungal activities. One of the compound is excellent antifungal agent against *Aspergillus flavus* (MIC value 10 mg/ml), *Candida albicans* (MIC value 20 mg/ml) as well

as against Aspergillus niger (MIC value 12.5 mg/ml) and Fusarium oxysporum (MIC value 25mg/ml). The other compound also shows good potency against Aspergillus niger (MIC value 10mg/ml) and Candida albicans (MIC value 20 mg/ml).

Pintilie and co-workers<sup>12</sup> synthesised 1,2,4-triazole compounds having a D,L-methionine moiety (4) and evaluated

them for antimicrobial activity using the strains Staphylococcus aureus ATCC 25923, Bacillus cereus ATCC 10987, Bacillus antracis ATCC 8705, Escherichia coli ATCC 25922 and Sarcina lutea ATCC 9341. Some of the synthesised compounds show excellent activities against Bacillus cereus and Bacillus antracis.

Zitouni and co-workers<sup>13</sup> have synthesised 4-phenyl/cyclohexyl-5-(1-phenoxyethyl)-3-[N-(2-thiazolyl)acetamido]thio-4- H-1,2,4-triazole derivatives (5) and evaluated them for antimicrobial activities against Candida glabrata, Candida albicans

(two strains), Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus. Among the synthesised compounds some of them showed excellent antifungal activities

Nguyen and co-workers<sup>14</sup> have synthesised triazole having carbohydrate phosphate esters (6) and evaluated for in vitro antifungal activity against *A. niger*, *C. albicans* and *Cryptococcus neoformans*. All the synthesised triazole derivatives were less active while diester and triester

derivatives were stronger against A. niger and C. albicans. The compound which having the substituent as  $R_1 = C_2H_4CN$ ,  $R_2 = nCH_2 = CH-C_9H_{18}$  which shows good activity as well as if  $R_1 = CH_3$  it also shows better activity with MIC values 258-1628 mg/ml.

Remi and co-workers<sup>15</sup> have synthesised substituted derivatives of 1-[((hetero)aryl- or piperidinylmethyl)aminol-2-phenyl-3-

(1H-1,2,4-triazol-1-yl)propan-2-ols (7) and screened them for antifungal activity against *A. fumigatus* and *C. albicans*. Compound with R = H,  $R_1 =$ 

Boc, X = F showed moderate antifungal activities against the used strains with

MIC values 3.8 to 33.0 mg/ml.

$$\begin{array}{c|c}
N & OH \\
N & X & R \\
X & 7 & R_1
\end{array}$$

 $co-workers^{16}$ Chandrika and have reported the synthesis of alkylated piperazines (8) and studied cytotoxicity against mammalian cells, hemolytic activity against murine ervthrocytes. All the synthesised

compounds were tested for antifungal activity and most of them showed better activity with MIC values against Aspergillus and non-albicans Candida strains

HO N 
$$Z = F, Cl$$
  $n = 0, 4, 7-13$ 

Jiang and co-workers<sup>17</sup> have synthesised the piperidine containing triazole (9) derivatives and tested them for antifungal activity. Many compounds showed excellent antifungal activity against a variety of clinically important fungal pathogens (*Trichophyton rubrum*,

Aspergillus fumigatus, Candida glabrata, Cryptococcus neoformans, Candida parapsilosis and Candida albicans). Some of the synthesised compounds were highly active fungal inhibitors

$$\bigcap_{N \in \mathbb{N}} \bigcap_{K \in \mathbb{N}} \bigcap_{N \in \mathbb{N}} \bigcap_{K \in \mathbb{N}} \bigcap_{$$

Che and co-workers<sup>18</sup> have reported the synthesis of a series of substituted phenoxypropyl piperazine (10) and evaluated for antifungal activity. In vitro evaluation of newly synthesised molecules showed moderate to good

activity. Most of the compounds showed highest activity against *Candida parapsilosis* and *Candida albicans*. Some of the compounds show more potency than standard itraconazole and fluconazole with the MIC values 0.06—

0.016 mg/ml, against *C. neoformans* is 0.06 mg/ml and against *A. fumigatus* in the range of 1–2 mg/ml. Compounds also show good activity against *dermatophytes*. Among all the

Chevreuil and his co-workers<sup>19</sup> have synthesised a series of 2-aryl-1-azolyl-3-thienylbutan-2-ols (11) then screened for their antifungal activity against both strains of *C. glabrata* and two other major human pathogenic fungi, *C. albicans* and *Aspergillus fumigatus*. The synthesised compounds

synthesised compounds 12i show excellent activity against *C. neoformans* is 0.06 mg/ml, and is comparable with voriconazole.

$$\begin{array}{lll} & 12a: R = 4\text{-}CH_3 & 12h: R = 4\text{-}NO_2 \\ 12b: R = 3\text{-}CH_3 & 12i: R = 4\text{-}C(CH_3)_3 \\ 12c: R = 2\text{-}CH_3 & 12j: R = 4\text{-}C1 \\ 12d: R = 3\text{-}Br & 12k: R = 2\text{-}Br \\ 12e: R = 4\text{-}F & 12l: R = 2\text{-}NO_2 \\ 12f: R = 2\text{-}Cl & 12n: R = 3\text{-}NO_2 \\ 12g: R = 4\text{-}Br & \end{array}$$

showed better activity, as well as good potency against the petite mutant, from that it is observed that they may overcome the increased expression of the efflux pumps basically observed in clinical yeast isolates resistant to current azoles.

Xu and co-workers<sup>20</sup> was synthesised a series of 1-(1*H*-1,2,4-triazole-1-yl)-2-(2,4-difluorophenyl)-3-substituted-2-propanols (12) and tested for in vitro antifungal activity against eight fungi strain (*C. albicans* 14053, *C. albicans* 20352, *Candida glabrata*, *Candida parapsilosis*, *Cryptococcus neoformans*,

Trichophyton rubrum, Aspergillus fumigatus and Microsporum gypseum). Most of the compounds were active towards all fungi to some extent, except C. glabrata and A. fumigatus. Halosubstituted compounds showed promising activities than remaining compounds

Ramirez-Villalva and co-workers<sup>21</sup> have synthesised 1,2,3-triazole-4,5-diphenyloxazol-2-one (13) containing series of compounds. Some of the

synthesised compounds showed excellent antifungal activities against the strains *M. hiemalis*, *C. glabrata* and *T. cutaneum*, while some of the

compounds are inactive against *C. utilis*, *C. krusei*, *C. albicans*, *C. tropicalis*, *A.* 

fumigatus, C. parapsilosis and R. oryzae.

N=N  

$$R_1$$
  $R_1$ = 2-NO<sub>2</sub>-Ph,  $R_2$ = SO<sub>2</sub>-4-Tol  
 $R_1$ = pentyl,  $R_2$ = SO<sub>2</sub>-Ph  
 $R_1$ = Ph,  $R_2$ = CN

Fu and co-workers<sup>22</sup> in their recent investigation, synthesise the series of 1-alkyl-1*H*-1,2,3-triazole-4-carboxylic acid with linear alkyl chain (14). The 1,2,3-triazoles with C8 and C10 linear alkyl chains shows inhibition of *C. albicans* cell growth as well as the

C10 alkyl chain compound, 1-decyl-1*H*-1,2,3-triazole-4-carboxylic acid showed the best activity for *C. albicans* with 90% inhibition, germ tube germination and inhibition of hyphal growth in *C. albicans*.

$$\begin{array}{c|c}
N & OH \\
\hline
N & OH \\
N & OH \\
\hline
N & OH \\
N & OH \\
\hline
N & OH \\
N & OH \\
\hline
N & OH \\
N & OH \\
\hline
N & OH \\
N & OH$$

Cao and co-workers<sup>23</sup> have synthesised 5,6-dihydro-4*H*-thieno[2,3-c]pyrrol-4-one ring or a 4,5-dihydro-6*H*-thieno[2,3-c]pyrrol-6-one ring compounds (**15**). These synthesised derivatives were potent against Candida

strains, including *C. glabrata*, *C. albicans* and *C. parapsilosis*. These compounds also show excellent activity against *C. neoformans* as well as *A. fumigatus*.

Gonzalez-Calderon and coworkers<sup>24</sup> have been synthesised series of 1,4,5-tri and 1,5-disubstituted triazole scaffold (**16**) by 1,3-dipolar cycloaddition of azide-enolate. The antifungal bioactive assay of these compounds was evaluated against fungi species *Mucor hiemalis* (ATCC-8690), *Trichosporon* 

cutaneum (ATCC-28592), Aspergillus fumigatus (ATCC-16907), Rhizopus oryzae (ATCC-10329) as well as candida species (three). This biological studies shows that some of the synthesised compounds showed good to excellent activity.

Zhang and co-workers<sup>25</sup> have synthesised a series of triazole (17) derivative which on antifungal screening shows excellent to good range of activities than reference drugs fluconazole and miconazole. The

compound 3,4-dichlorobenzyl derivative (5b) showed excellent activity against fungal strains (*C. mycoderma*, *Beer yeast*, *A. flavus*, *C. utilis* and *C. albicans*).

$$\begin{array}{c} R_3 \\ R_2 \\ R_2 \\ R_3 \\ R_4 \\ R_5 \\ R_6 \\ R_7 \\ R_8 \\ R_9 \\$$

Wu and co-workers<sup>26</sup> have designed and synthesised series of voriconazole analogues, (2R,3R)-1-(1*H*-1,2,4-triazol-1-yl)-2-(2,4-difluorophenyl)-3-(*N*-substituted)-2-butanols (18) and screened them for antifungal activity.

Some of the synthesised compounds showed better activities as compared to fluconazole while some of the compounds showed significant activity against *Aspergillus fumigatus*.

18

Aher and co-workers<sup>27</sup> have synthesised potent antifungal agent containing 1,2,3-triazole (**19**) motif. All the synthesised compounds were tested for in vitro antifungal activity against

Candida fungal pathogens then on further structural modifications these compounds were screened in vivo against *Candida albicans*.

Ezabadi and co-workers<sup>28</sup> synthesised new series of 5-[2-(substituted sulfamoyl)-4,5-dimethoxybenzyl]-4-aryl-1,2,4-triazole-3-thiones (**20**) and screened for antifungal activity (In vitro) against *Aspergillus versicolor*, *Aspergillus niger*, *Aspergillus flavus*,

Aspergillus ochraceus, Penicillium funiculosum and Trichoderma viride. The 1,2,4-triazole molecule containing chloro functionality shows higher activity as compared to others

$$N-NH$$
 $SO_2$ 
 $N(Et)_2$ 
 $OCH_3$ 
 $N-NH$ 
 $N$ 
 $S$ 
 $OCH_3$ 
 $OCH_3$ 

Holla and co-workers<sup>29</sup> synthesized triazole scaffold (**21**) and screened for antifungal activity against the fungal strain *Candida albicans*. Among the synthesised triazole derivatives below compounds 1-(1-(8-trifluoromethylquinolin-4-yl)-5-methyl-

 $1H\text{-}1,2,3\text{-}\text{triazole-}4\text{-}\text{yl})\text{-}4\text{-}\text{(thiophen-}3\text{-}\text{yl})\text{but-}2\text{-}\text{en-}1\text{-}\text{one} \quad \text{and} \quad 1\text{-}(8\text{-}\text{trifluoromethylquinolin-}4\text{-}\text{yl})\text{-}N\text{-} \quad (2\text{-}\text{(thiophen-}3\text{-}\text{yl})\text{ethylidene})\text{-}1H\text{-}1,2,3\text{-}\text{triazole-}4\text{-}\text{carbohydrazide showed better antifungal activity.}}$ 

Hussain and co-workers<sup>30</sup> have synthesised amino substituted 1,2,4-triazole derivatives (22) and screened them for antifungal activity against

Aspergillus niger. Chloro substituted triazole compound shows 25 µg/ml minimum inhibitory concentration (MIC) against the strain species

#### **Conclusions and Future Prospects**

Triazole is a vital class of five membered heterocyclic compound having nitrogen atoms. Due to potent biological associated activities with triazole containing derivatives. becomes pharmacophore in important the medicinal field. In present review we have focused on various triazole and their derivatives along with their broad spectrum of activities. The information provided in this article can be useful for researchers for getting an idea about structural modifications to discover potent lead components which is useful in medicinal field.

#### References

- 1. Niwa, T., Shiraga, T., & Takagi, A. (2005). Effect of Antifungal Drugs on Cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 Activities in Human Liver Microsomes. Biological and Pharmaceutical Bulletin, 28, pp1805-1808.
- 2. Maste M. M., Ainapure, R., Patil, P. B. & Bhat, A. R. (2011). Triazolone and their Derivatives for Anti-Tubercular Activities. Asian Journal of Research in Chemistry, 4, pp1050-1054.
- 3. Nair, H. K., Peterson, A. C., Yazdi, P. T., & Franzmair, R. (1997). Imidazole and triazole substituted ether phospholipids: potent antitumor agents. Bioorganic & Medicinal Chemistry Letters, 7, pp2379–2382.
- 4. Palaska, E., Sahin, G., Kelicen, P., Durlu, N. T., & Altinok, G. (2002). Synthesis and anti-inflammatory activity of 1-acylthiosemicarbazides, 1,3,4-oxadiazoles, 1,3,4-thiadiazoles

- and 1,2,4-triazole-3-thiones. Il Farmaco, 57, pp101-107.
- 5. Klimesova, V., Zahajska, L., Waisser, K., Kaustova, J., & Mollmann, U. (2004). Synthesis and antimycobacterial activity of 1,2,4-triazole 3-benzylsulfanyl derivatives. Il Farmaco, 59, pp279-288.
- 6. Xia, Y., Fan, Z., & Peng, L. (2006). Discovery of bitriazolyl compounds as novel antiviral candidates for combating the tobacco mosaic virus. Bioorganic & Medicinal Chemistry Letters, 16, pp2693-2698.
- Patil, V., Guerrant, W., Chen, P. C., Gryder, B., Benicewicz, D. B., Khan, S. I., Tekwani, B. L., & Oyelere, A. K. (2010). Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazolelinked cap group. Bioorganic & Medicinal Chemistry, 18, pp415– 425.
- 8. Jamkhandi, C. M., & Disouza, J. I. (2013). Evaluation of Antioxidant Activity for Some Benzotriazole Substituted with N-Phenylacetamide and acetylcarbamic acid Derivatives. International Journal of Pharmacy and Pharmaceutical Sciences, 5, pp249-253.
- Isloor, A. M., Kalluraya, B., & Shetty, P. (2009). Regioselective Reaction: Synthesis, characterization and pharmacological studies of some new Mannich Bases derived from 1,2,4-triazoles. European Journal of Medicinal Chemistry, 44, pp3784– 3787.
- 10. Demirayak, S., Benkli, K., & Guven, K. (2000). Synthesis and antimicrobial activities of some 3-

- arylamino-5-[2-(substituted 1-imidazolyl)ethyl]-1,2,4-triazole derivatives. European Journal of Medicinal Chemistry, 35, pp1037–1040
- 11. Sangshetti, J. N., Nagawade, R. R., & Shinde, D. B. (2009). Synthesis of novel 3-(1-(1-substituted piperidin-4-yl)-1*H*-1,2,3-triazol-4-yl)-1,2,4-oxadiazol-5(4*H*)-one as antifungal agents, Bioorganic & Medicinal Chemistry Letters, 19, pp3564–3567.
- 12. Pintilie, O., Profire, L., Sunel, V., Popa, M., & Pui, A. (2007). Synthesis and antimicrobial activity of some new 1,3,4-thiadiazole and 1,2,4-triazole compounds having a D,L-methionine moiety. Molecules, 12, 103–113.
- 13. Zitouni, G. T., Chevallet, P., & Kaya, D. (2005).Synthesis and antimicrobial activity 4phenyl/cyclohexyl-5-(1phenoxyethyl)-3-[N-(2thiazolyl)acetamidolthio-4H-1,2,4triazole derivatives. European Journal of Medicinal Chemistry, 40, pp607-613.
- 14. Nguyen, N., Soroush, S., Meredith, S., & Keykavous, P. (2004). Carboxylic acid and phosphate ester derivatives of fluconazole: synthesis and antifungal activities. Bioorganic & Medicinal Chemistry, 12, pp6255-6269.
- 15. Guillon, R., Giraud, F., Loge, C., Borgne, M. L., Picot, C., Pagniez, F., & Pape, P. L. (2009). Design of new antifungal agents: synthesis and evaluation of 1-[(1*H*-indol-5-ylmethyl)amino]-2-phenyl-3-(1*H*-1,2,4-triazol-1-yl)propan-2-ols. Bioorganic & Medicinal Chemistry Letters, 19, pp5833-5836.
- 16. Chandrika, N. T., Shrestha, S. K., Ngo, H. X., Tsodikov, O. V., Howard, K. C., & Tsodikova, S. G. (2018). Alkylated Piperazines and Piperazine-Azole Hybrids as Antifungal Agents. Journal of Medicinal Chemistry. 61, pp158–173

- 17. Jiang, Z., Gu, J., Wang, C., Wang, S., Liu, N., Jiang, Y., Dong, G., Wang, Y., Liu, Y., Yao, J., Miao, Z., Zhang, W., & Sheng, C. (2014). Design, synthesis and antifungal activity of novel triazole derivatives containing substituted 1,2,3-triazole-piperdine side chains. European Journal of Medicinal Chemistry. 82, pp490-497.
- 18. Che, X., Sheng, C., Wang, W., Cao, Y., Xu, Y., Ji, H., Dong, G., Miao, Z., Yao, J., & Zhang, W. (2009). New azoles with potent antifungal activity: Design, synthesis and docking. molecular European Journal of Medicinal Chemistry. 44, pp4218-4226.
- 19. Chevreuil, F., Landreau, A., Seraphin, D., Larcher, G., Bouchara, J. & Richomme, P. (2006). Synthesis and antifungal activity of new thienyl and aryl conazoles. Journal of Enzyme Inhibition and Medicinal Chemistry. 21, pp293-303.
- 20. Xu, K., Huang, L., Xu, Z., Wang, Y., Bai, G., Wu, Q., Wang, X., Yu, S., & Jiang, Y. (2015). Design, synthesis, and antifungal activities of novel triazole derivatives containing the benzyl group. Drug Design, Development and Therapy, 9, pp1459–1467
- 21. Ramirez-Villalva, A., Gonzalez-Calderon, D., Rojas-Garcia, R. I., Gonzalez-Romero, C., Tamariz-Mascarua, J., Morales Rodriguez, M., & Zavala-Segovia. N., Fuentes-Benites, A. (2017). Synthesis and antifungal activity of oxazolidin-2-one-linked 1,2,3-triazole derivatives. Medicinal Chemistry Communications. 8, pp2258–2262.
- 22. Fu, N., Wang, S., Zhang, Y., Zhang, C., Yang, D., Weng, L., Zhao, B., & Wang, L. (2017). Efficient click chemistry towards fatty acids containing 1,2,3-triazole: Design and synthesis as potential antifungal for Candida drugs albicans. European Journal of Medicinal Chemistry. 136, pp596–602.

- 23. Cao, X., Xu, Y., Cao, Y., Wang, R., Zhou, R., Chu, W., & Yang, Y. (2015). Design, synthesis and structure-activity relationship study of novel thienopyrrolidone derivatives with strong antifungal activity against Aspergillus fumigates. European Journal of Medicinal Chemistry. 102, pp471–476.
- 24. Gonzalez-Calderon, D., Meiia-Dionicio, M. G., Morales-Reza, M. A., Ramirez-Villalva, A., Morales-Rodriguez, M., Jauregui-Rodriguez, В., Diaz-Torres, E., Gonzalez-Romero, C., & Fuentes Benites, A. Azide-enolate 1,3-dipolar cycloaddition in the synthesis of novel triazole-based miconazole analogues as promising antifungal European Journal agents. Medicinal Chemistry. 112, pp60–65.
- 25. Zhang, Y., Damu, G. L. V., Cui, S. F., Mi, J. L., Tangadanchu, V. K. R., & Zhou, C. H. (2017). Discovery of potential antifungal triazoles: design, synthesis, biological evaluation. and preliminary antifungal mechanism exploration. Medicinal Chemistry Communications. 8, pp1631–1639.
- 26. Wu, J., Ni, T., Chai, X., Wang, T., Wang, H., Chen, J., Jin, Y., Zhang, D., Yu, S., & Jiang, Y. (2018). Molecular docking, design, synthesis and antifungal activity study of novel triazole derivatives. European Journal of Medicinal Chemistry. 143, pp1840-1846.
- 27. Aher, N., Pore, V., Mishra, N., Kumar, A., Shukla, P., Sharma, A., & Bhat, M. (2009). Synthesis and antifungal activity of 1,2,3-triazole containing fluconazole analogues. Bioorganic & Medicinal Chemistry Letters. 19, pp759-763.
- 28. Ezabadi, I. R., Camoutsis, C., Zoumpoulakis, P., Geronikaki, A., Sokovic, M., Glamocilija, J., & Ciric, A. (2008). Sulfonamide-1,2,4-triazole derivatives as antifungal and antibacterial agents: Synthesis,

- biological evaluation, lipophilicity, and conformational studies. Bioorganic & Medicinal Chemistry. 16, pp1150–1161.
- 29. Holla, B. S., Mahalinga, M., Karthikeyan, M. S., Poojary, B., Akberali, P. M., & Kumari, N. S. (2005). Synthesis, characterization and antimicrobial activity of some substituted 1,2,3-triazoles. European Journal of Medicinal Chemistry. 40, pp1173–1178.
- 30. Hussain, S., Sharma, J., & Amir, M. (2008). Synthesis and Antimicrobial Activities of 1,2,4-Triazole and 1,3,4-Thiadiazole Derivatives of 5-Amino-2-Hydroxybenzoic Acid. Journal of Chemistry. 5, pp963–968.